January 30, 2007 -- Alfacell won Orphan Drug designation for cancer drug Onconase; Critical Therapeutics out-licensed its vagus nerve stimulation IP to Innovative Metabolics; BioSante reported positive pre-clinical results for a flu vaccine adjuvant, BioVant; Compugen will collaborate with Teva to discover biomarkers that detect drug toxicity; Teva received approval of a generic version of an ADHD drug; Exelixis submitted an IND for a new anti-cancer therapy; Lexicon Genetics began a Phase Ib trial of an oral drug that treats the cognitive impairment of Alzheimer’s; ZymoGenetics put its hepatitis C candidate into a Phase I trial; Merck Serono launched easypod, an injection device for the once-daily administration of a growth hormone; Threshold began a Phase II trial of glufosfamide in patients with platinum-resistant ovarian cancer; and Immtech Pharma completed enrollment in a Phase III trial of an oral drug for African sleeping sickness. The Centient Biotech 200™ rose 25 points to 4033, a gain of .60%. More details...
